How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

14,624 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy. (Abstract)

Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy. To investigate the renal protective effects of early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN).Medical data of 57 SLE patients with biopsy-proven aPLN were analyzed

2018 Journal of Rheumatology

142. TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis. (Abstract)

TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis. Upregulation of type I interferons (IFN-I) is a hallmark of systemic autoimmune diseases like primary Sjögren's syndrome (pSS), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Expression of IFN-I is induced by three different receptor families: Toll-like receptors (TLRs), RIG-like receptors (RLRs) and DNA-sensing receptors (DSRs (...) downregulated the expression of the ISGs MxA, IFI44, IFI44L, IFIT1 and IFIT3.TBK1 inhibition reduced expression of ISGs in PBMCs from IFNpos patients with systemic autoimmune diseases indicating TBK1 as a potential treatment target.Copyright © 2018 Elsevier Ltd. All rights reserved.

2018 Journal of Autoimmunity

143. Feasibility, Validity, and Reliability of the 10-item Patient Reported Outcomes Measurement Information System Global Health Short Form in Outpatients with Systemic Lupus Erythematosus. Full Text available with Trip Pro

Feasibility, Validity, and Reliability of the 10-item Patient Reported Outcomes Measurement Information System Global Health Short Form in Outpatients with Systemic Lupus Erythematosus. To assess the feasibility, validity, and reliability of the Patient Reported Outcomes Measurement Information System Global Health Short Form (PROMIS10) in outpatients with systemic lupus erythematosus (SLE).SLE outpatients completed PROMIS10, Medical Outcomes Study Short Form-36 (SF-36), LupusQoL-US

2018 Journal of Rheumatology

144. The role of ophthalmic imaging in central nervous system degeneration in systemic lupus erythematosus. Full Text available with Trip Pro

The role of ophthalmic imaging in central nervous system degeneration in systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disorder that can involve any organ system. Central nervous system involvement can be a severe life threatening complication, ultimately resulting in severe neurodegenerative changes. Magnetic resonance imaging suggests that neurodegeneration, which may have deleterious effects on brain function, may occur early in SLE (...) activity. The authors aim to review the current understanding of neurodegeneration associated with SLE, with particular focus on the visual pathway. We describe the neuropathology of the visual system in SLE and the evidence for retinal and choroidal neurodegenerative and microvascular changes using optical coherence tomography technology. We aim to describe the potential role of optical imaging modalities in NPSLE diagnosis and their likely impact on the study of neuronal function.Copyright © 2018

2018 Autoimmunity reviews

145. Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. (Abstract)

Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are two phenotypically distincts inflammatory systemic diseases. However, SLE and SSc share pathogenic features such as interferon signature, loss of tolerance against self-nuclear antigens and increased tissue damage such as fibrosis. Recently, platelets have emerged as a major actor in immunity including auto-immune diseases. Both SLE and SSc (...) are characterized by strong platelet system activation, which is likely to be both the witness and culprit in their pathogenesis. Platelet activation pathways are multiple and sometimes redundant. They include immune complexes, Toll-like receptors activation, antiphospholipid antibodies and ischemia-reperfusion associated with Raynaud phenomenon. Once activated, platelet promote immune dysregulation by priming interferon production by immune cells, providing CD40L supporting B lymphocyte functions and providing

2018 Autoimmunity reviews

146. Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjogren's Syndrome: A General Population-Based Study. Full Text available with Trip Pro

Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjogren's Syndrome: A General Population-Based Study. To determine excess productivity losses and costs of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjögren's syndrome (SS) at the population level.Administrative databases from the province of British Columbia, Canada, were used to establish population-based cohorts of SLE, SSc, and SS, and matched comparison cohorts were selected from

2018 Arthritis care & research

147. A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus. (Abstract)

A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus. Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that varies markedly in severity and can be difficult to both diagnose and treat (1, 2). Many manifestations of SLE result from well-defined immune mechanisms that drive systemic as well as local inflammation. If not adequately controlled, these manifestations can lead to organ injury and dysfunction (3). Other manifestations of SLE are vague in origin

2018 Arthritis care & research

148. Psychometric evaluation of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS<sup>®</sup> ) in a multi-racial, multi-ethnic systemic lupus erythematosus (SLE) cohort. (Abstract)

Psychometric evaluation of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS® ) in a multi-racial, multi-ethnic systemic lupus erythematosus (SLE) cohort. We examined psychometric performance of PROMIS measures in a racially/ethnically, linguistically diverse SLE cohort.Data were from the California Lupus Epidemiology Study (CLUES), a multi-racial/ethnic cohort of individuals with physician-confirmed SLE. The majority (n=332) attended in-person research visits (...) groups. Minimal floor effects were observed, but ceiling effects were noted. Missing item responses were minimal for most scales, except for items related to work. No differences were noted by mode of administration or by language of administration among Hispanics and Asians. After accounting for differences in disease status, age, and sex, few differences in mean scores between whites and other racial/ethnic groups were noted.PROMIS measures appear reliable and valid in lupus across racial/ethnic

2018 Arthritis care & research

149. Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis

Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis (MICROLUPS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03575156

2018 Clinical Trials

150. Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature. Full Text available with Trip Pro

Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature. Primary central nervous system lymphoma (PCNSL) is a rare disease. Studies of PCNSL in patients with rheumatic diseases are lacking. Neither clinical symptoms nor radiographic manifestation is specific to PCNSL. Therefore, it could be misdiagnosed with other diseases such as brain tumors. Chemotherapy is the primary treatment for PCNSL (...) , while the role of surgery remains controversial.We reported a 39-year-old woman with systemic lupus erythematosus (SLE) developed PCNSL after 15-year treatment with multiple immunosuppressants.Cranial magnetic resonance imaging (MRI) showed multi-focal lesions with ring-like enhancement post-contrast in the right hemisphere, which mimicked glioma radiographically. Owing to the severe symptoms of intracranial hypertension, gross tumor resection was performed. Pathological exam showed perivascular

2018 Medicine

151. Efficacy and safety of Anti-Interferon-alpha Receptor Monoclonal Antibody in systemic lupus erythematosus: A system review and meta analysis

Efficacy and safety of Anti-Interferon-alpha Receptor Monoclonal Antibody in systemic lupus erythematosus: A system review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

152. Prediction of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus. (Abstract)

Prediction of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus. Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease associated with major obstetrical complications such as gestational loss, preterm delivery, fetal growth restriction (FGR) and preeclampsia. Published literature is not consensual regarding the main risk factors for each of these outcomes. Our goal with this study was to determine the most important predictors for each of the main adverse (...) to determine statistical significance, and two-sided confidence intervals of 95% are reported. In our cohort, the main risk factors for gestational loss were maternal age and the presence of antiphospholipid antibodies. Lupic nephritis was predictive of a preterm delivery and preeclampsia. Renal involvement and lupus flares during pregnancy were risk factors for FGR. Overall, the main risk factor for an adverse pregnancy outcome were lupus flares during pregnancy. Despite optimal pregnancy monitoring

2019 Clinical Reviews in Allergy & Immunology

153. Role of <i>CTLA4</i> A49G polymorphism in systemic lupus erythematosus and its geographical distribution. (Abstract)

Role of CTLA4 A49G polymorphism in systemic lupus erythematosus and its geographical distribution. CTLA-4 (cytotoxic T-lymphocyte-associated protein-4) or CD152 is an inhibitory receptor expressed constitutively on CD4+ CD25+ T regulatory lymphocytes and transiently on activated CD4+ and CD8+ T lymphocytes. Its inhibitory function promotes long-lived anergy in immune cells and prevents autoimmunity. Therefore, it plays a crucial role in T cell-mediated autoimmunity, and thus (...) in susceptibility to autoimmune diseases, including systemic lupus erythematosus (SLE). It is encoded by CTLA4 gene in humans. AtoG polymorphism at position +49 of CTLA4 gene is the only polymorphism which changes amino acid sequence from alanine to threonine in the leader sequence, which may affect the function of CTLA-4. Association of CTLA4 polymorphisms with SLE has been investigated in several reports in different ethnic populations from different countries, which have shown highly inconsistent findings

2019 Journal of Clinical Pathology

154. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Full Text available with Trip Pro

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. This extension study of the Phase III, randomized, placebo-controlled Belimumab International SLE Study (BLISS)-52 and BLISS-76 studies allowed non-US patients with SLE to continue belimumab treatment, in order to evaluate its long-term safety and tolerability including organ damage accrual.In this multicentre, long-term extension study (GlaxoSmithKline

2019 Rheumatology (Oxford, England) Controlled trial quality: uncertain

155. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Full Text available with Trip Pro

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Previous reports have described the appearance of systemic lupus erythematosus (SLE) cases following interferon-α (IFN-α) therapy, IFN-regulated gene expression is significantly increased in SLE, and an association between SLE and gene variants belonging to IFN downstream pathways has been shown. Based on this, targeting of IFN and of their signaling pathways has (...) been assessed in 11 clinical studies: 9 in SLE, 1 in systemic sclerosis and 1 in rheumatoid arthritis. In SLE, clinical development reached Phase I for 1 study and Phases II and III for 5 and 3 trials, respectively. The Phase IIb, randomized control trial (RCT), double-blind, placebo-controlled study of adults with moderate-to-severe SLE (MUSE trial) showed positive results on the composite primary endpoint SRI-4. Greater efficacy was seen in patients with high baseline IFN gene signature compared

2019 Drug design, development and therapy Controlled trial quality: uncertain

156. Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China. (Abstract)

Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China. Background For the large number of systemic lupus erythematosus (SLE) patients in China, it is critical to carry out effective disease management to improve the treatment effect and reduce disease burden. A pharmacist-led multidisciplinary care model has not been reported in Chinese SLE patients before. Objective To assess the effect of patient-centered, pharmacist-led (...) , multidisciplinary care on clinical outcomes and satisfaction with health care in Chinese SLE patients. Setting: The South Campus, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Method Participants were 143 systemic lupus erythematosus patients randomly assigned to either the intervention group (multidisciplinary care: physician, pharmacist and nurse) or the control group (usual care only). Main outcome measures The primary outcome was scores on the systemic lupus

2019 International journal of clinical pharmacy Controlled trial quality: predicted high

157. Pseudo-pseudo Meigs' syndrome presenting with a combination of polyserositis, elevated serum CA 125 in systemic lupus erythematosus: A case report. Full Text available with Trip Pro

Pseudo-pseudo Meigs' syndrome presenting with a combination of polyserositis, elevated serum CA 125 in systemic lupus erythematosus: A case report. Combination of polyserositis and elevated serum CA 125 is common in tumor or infectious disease, but this clinical combination is also found in other diseases. It could be the initial manifestation of pseudo-pseudo Meigs' syndrome (PPMS), which is characterized by the presence of polyserositis and raised CA-125 level in systemic lupus erythematosus

2019 Medicine

158. A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report. Full Text available with Trip Pro

A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report. Gain of function (GOF) mutations in PIK3CD gene encoding PI3K p110δ were recently associated with a novel combined immune deficiency characterized by recurrent sinopulmonary infections, CD4 lymphopenia, reduced class-switched memory B cells, lymphadenopathy, cytomegalovirus and/or epstein-Barr virus (EBV) viremia, and EBV-related lymphoma. A subset of affected patients also had elevated serum IgM.We report (...) a patient who was diagnosed with systemic lupus erythematosus (SLE) at a young age and was recently found to carry heterozygous mutations in PIK3CD. The patient not only presented with recurrent sinopulmonary infections, CD4 lymphopenia, lymphadenopathy, EBV viremia, and elevated serum IgM, but also met classification criteria of SLE based on persistent proteinuria and hematuria, leukopenia and anemia, low level of serum complement, and positive autoantibody for antinuclear antibodies.Activated PI3Kδ

2019 Medicine

159. Incomplete systemic lupus erythematosus - what remains after application of ACR and SLICC criteria? Full Text available with Trip Pro

Incomplete systemic lupus erythematosus - what remains after application of ACR and SLICC criteria? Incomplete systemic lupus erythematosus (iSLE) is an acknowledged condition of patients with clinical signs of lupus who do not fulfill classification criteria for SLE. Some iSLE patients have persistent mild disease, but others have serious organ involvement, and up to 55% progress to established SLE. Research on this subject could reveal predictive or diagnostic biomarkers for SLE. Ideally (...) , it would become possible to discriminate those patients with critical organ involvement or a high risk for progression to SLE. This "high risk" group might benefit from early treatment, which would preferably be confirmed in randomized controlled trials. However, this requires agreement on a definition of iSLE. The Systemic Lupus International Collaborating Clinics (SLICC) classification criteria was composed in order to diagnose SLE earlier. This review outlines the clinical characteristics of iSLE

2019 Arthritis care & research

160. Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus. (Abstract)

Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus. This study aimed to: 1) determine the prevalence of depression and anxiety in SLE patients using the Center for Epidemiological Studies-Depression Scale [CES-D], Hospital Anxiety and Depression Scale [HADS], and Beck Anxiety Inventory [BAI] questionnaires; 2) study the criterion validity, interpretability, and test-retest reliability of CES-D, HADS and BAI; and 3

2019 Seminars in arthritis and rheumatism

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>